Mergers & Acquisitions Mergers & Acquisitions

Illumina, Grail order to unwind deal by US FTC still faces federal court scrutiny

The US Federal Trade Commission today ordered Illumina to unwind its acquisition of cancer healthcare company Grail, reversing a decision by its administrative law judge that allowed the $8 billion deal to proceed.
But the order still faces federal court scrutiny, as the companies said they will appeal the decision

To view the latest version of this document and thousands of others like it, sign-in to MLex or register for a free trial.

Discover MLex

Stay on top of global regulatory developments

Latest News